Stroke - Pipeline Review, H1 2018

Publisher Name :
Date: 06-Mar-2018
No. of pages: 456
Inquire Before Buying

Stroke - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H1 2018, provides an overview of the Stroke (Cardiovascular) pipeline landscape.

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Stroke - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 22, 21, 2, 90, 12 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 27 and 3 molecules, respectively.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Stroke - Pipeline Review, H1 2018

Table of Contents
Table of Contents 2
Introduction 6
Stroke - Overview 7
Stroke - Therapeutics Development 8
Stroke - Therapeutics Assessment 31
Stroke - Companies Involved in Therapeutics Development 47
Stroke - Drug Profiles 81
Stroke - Dormant Projects 413
Stroke - Discontinued Products 424
Stroke - Product Development Milestones 427
Appendix 437

List of Tables
Number of Products under Development for Stroke, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Stroke - Pipeline by Acorda Therapeutics Inc, H1 2018
Stroke - Pipeline by Acticor Biotech SAS, H1 2018
Stroke - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2018
Stroke - Pipeline by Addex Therapeutics Ltd, H1 2018
Stroke - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2018
Stroke - Pipeline by Affibody AB, H1 2018
Stroke - Pipeline by Anavex Life Sciences Corp, H1 2018
Stroke - Pipeline by Angion Biomedica Corp, H1 2018
Stroke - Pipeline by Antoxis Ltd, H1 2018
Stroke - Pipeline by AptaTargets SL, H1 2018
Stroke - Pipeline by ArmaGen Inc, H1 2018
Stroke - Pipeline by Artelo Biosciences Inc, H1 2018
Stroke - Pipeline by ArunA Biomedical Inc, H1 2018
Stroke - Pipeline by AstraZeneca Plc, H1 2018
Stroke - Pipeline by Athersys Inc, H1 2018
Stroke - Pipeline by Biogen Inc, H1 2018
Stroke - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Stroke - Pipeline by Cardax Inc, H1 2018
Stroke - Pipeline by CHA Bio & Diostech Co Ltd, H1 2018
Stroke - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Stroke - Pipeline by DiaMedica Therapeutics Inc, H1 2018
Stroke - Pipeline by Diffusion Pharmaceuticals Inc, H1 2018
Stroke - Pipeline by Epigen Biosciences Inc, H1 2018
Stroke - Pipeline by Evgen Pharma Plc, H1 2018
Stroke - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Stroke - Pipeline by Fina Biotech SL, H1 2018
Stroke - Pipeline by GC Pharma, H1 2018
Stroke - Pipeline by Genervon Biopharmaceuticals LLC, H1 2018
Stroke - Pipeline by Glialogix Inc, H1 2018
Stroke - Pipeline by Glucox Biotech AB, H1 2018
Stroke - Pipeline by Immunwork Inc, H1 2018
Stroke - Pipeline by International Stem Cell Corp, H1 2018
Stroke - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018
Stroke - Pipeline by JT Pharmaceuticals Inc, H1 2018
Stroke - Pipeline by Les Laboratoires Servier SAS, H1 2018
Stroke - Pipeline by Living Cell Technologies Ltd, H1 2018
Stroke - Pipeline by Lumosa Therapeutics Co Ltd, H1 2018
Stroke - Pipeline by M et P Pharma AG, H1 2018
Stroke - Pipeline by Magnus Life Ltd, H1 2018
Stroke - Pipeline by Mapreg SAS, H1 2018
Stroke - Pipeline by Meridigen Biotech Co Ltd, H1 2018
Stroke - Pipeline by Neuralstem Inc, H1 2018
Stroke - Pipeline by Neuren Pharmaceuticals Ltd, H1 2018
Stroke - Pipeline by Neurofx Inc, H1 2018
Stroke - Pipeline by Neuronax SAS, H1 2018
Stroke - Pipeline by NeuroSearch A/S, H1 2018
Stroke - Pipeline by New World Laboratories Inc, H1 2018
Stroke - Pipeline by NoNO Inc, H1 2018
Stroke - Pipeline by Novartis AG, H1 2018
Stroke - Pipeline by Noxopharm Ltd, H1 2018
Stroke - Pipeline by NuvOx Pharma LLC, H1 2018
Stroke - Pipeline by Omniox Inc, H1 2018
Stroke - Pipeline by Pharmagenesis Inc, H1 2018
Stroke - Pipeline by Pharmaxis Ltd, H1 2018
Stroke - Pipeline by Pharmicell Co Ltd, H1 2018
Stroke - Pipeline by Phoenix Biotechnology Inc, H1 2018
Stroke - Pipeline by PhytoHealth Corp, H1 2018
Stroke - Pipeline by Pluristem Therapeutics Inc, H1 2018
Stroke - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2018
Stroke - Pipeline by ReNeuron Group Plc, H1 2018
Stroke - Pipeline by Rich Pharmaceuticals Inc, H1 2018
Stroke - Pipeline by Rubicon Biotechnology Inc, H1 2018
Stroke - Pipeline by SanBio Inc, H1 2018
Stroke - Pipeline by Saneron CCEL Therapeutics Inc, H1 2018
Stroke - Pipeline by Savara Inc, H1 2018
Stroke - Pipeline by Shin Poong PharmCo Ltd, H1 2018
Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2018
Stroke - Pipeline by Spectrum Pharmaceuticals Inc, H1 2018
Stroke - Pipeline by Stemedica Cell Technologies Inc, H1 2018
Stroke - Pipeline by SynZyme Technologies LLC, H1 2018
Stroke - Pipeline by TaiGen Biotechnology Co Ltd, H1 2018
Stroke - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018
Stroke - Pipeline by Tenax Therapeutics Inc, H1 2018
Stroke - Pipeline by TikoMed AB, H1 2018
Stroke - Pipeline by Verseon Corp, H1 2018
Stroke - Pipeline by Vicore Pharma AB, H1 2018
Stroke - Pipeline by Virogenomics BioDevelopment Inc, H1 2018
Stroke - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2018
Stroke - Pipeline by Zocere Inc, H1 2018
Stroke - Dormant Projects, H1 2018
Stroke - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Stroke, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
  • Global Restless Legs Syndrome Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 112
    According to our LPI (LP Information) latest study, the global Restless Legs Syndrome market size was valued at US$ million in 2023. With growing demand in downstream market, the Restless Legs Syndrome is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Restless Legs Syndrome market. Restless Legs Syndrome are expected to show stable growth in the future market. However, product di......
  • Global Autism Spectrum Disorder Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 110
    Report Overview: Autism spectrum disorder is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests and activities. Diagnosing autism spectrum disorder (ASD) can be difficult, since there is no medical test, like a blood test, to diagnose the disorders. Doctors look at the child's behavior and development to make a diagnosis. Our report studies the market......
  • Global Epilepsy Therapeutics Market Research Report 2023
    Published: 14-Dec-2023        Price: US 2900 Onwards        Pages: 86
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Epilepsy Therapeutics market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Abbott Laboratories - Cephalon - Novartis - Pfizer - Johnson & Johnson - GlaxoSmithKline - Sanofi - Sunovion Pharmaceuticals......
  • Global Autism Spectrum Disorder Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 109
    Market Overview of Global Autism Spectrum Disorder market: According to our latest research, the global Autism Spectrum Disorder market looks promising in the next 5 years. As of 2022, the global Autism Spectrum Disorder market was estimated at USD 464.19 million, and it's anticipated to reach USD 700.88 million in 2028, with a CAGR of 7.11% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of ......
  • Global Autism Spectrum Disorder Market Status and Outlook 2023-2028
    Published: 24-Nov-2023        Price: US 3160 Onwards        Pages: 109
    Autism spectrum disorder (ASD) is a complex developmental condition that involves persistent challenges in social interaction, speech and nonverbal communication, and restricted/repetitive behaviors. The effects of ASD and the severity of symptoms are different in each person. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segmen......
  • Global Epilepsy Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 112
    Market Overview of Global Epilepsy Therapeutics market: According to our latest research, the global Epilepsy Therapeutics market looks promising in the next 5 years. As of 2022, the global Epilepsy Therapeutics market was estimated at USD 11157.84 million, and it's anticipated to reach USD 13510.46 million in 2028, with a CAGR of 3.24% during the forecast years. Epilepsy is a group of neurological disorders characterized by seizures. The onset of a seizure can range from a b......
  • Global Gabapentin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Oct-2023        Price: US 3380 Onwards        Pages: 98
    Market Overview of Global Gabapentin market: According to our latest research, the global Gabapentin market looks promising in the next 5 years. As of 2022, the global Gabapentin market was estimated at USD 1627.13 million, and it's anticipated to reach USD 1844.92 million in 2028, with a CAGR of 2.12% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Gabapentin market, with a sys......
  • 2023-2031 Report on Global Autism Spectrum Disorder Market by Player, Region, Type, Application and Sales Channel
    Published: 09-Oct-2023        Price: US 2500 Onwards        Pages: 89
    This report studies the Autism Spectrum Disorder market, covering market size for segment by type (Center-Based, In-Home, etc.), by application (1-14 Years Old, 15-25 Years Old, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Otsuka, Astrazeneca, Pfizer, Eli Lilly, Johnson & Johnson, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Aut......
  • Global Gabapentin Market Insights, Forecast to 2029
    Published: 27-Sep-2023        Price: US 4900 Onwards        Pages: 112
    Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain. The global Gabapentin market is projected to grow from US$ 1572.1 million in 2023 to US$ 1749.7 million by 2029, at a Compound Annual Growth Ra......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs